Sales representatives for Dyanavel extended-release told physicians the drug worked faster than other ADHD medications and other unproven benefits, according to the lawsuit.
The alleged “false and/or misleading messages regarding the efficacy of Dyanavel XR were disseminated repeatedly on thousands of sales calls to Texas Medicaid providers and decision makers,” the lawsuit says.
A second lawsuit accuses Tris of altering quality control results as tests were showing another ADHD drug, Quillivant, failing to dissolve. Despite this, Pfizer allegedly persuaded Texas’ Medicaid program to add the medication to its list of preferred drugs.
Pfizer said it plans to dismiss the charges.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
